NASDAQ:APLT Applied Therapeutics - APLT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.81 +0.01 (+1.25%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.76▼$0.8550-Day Range$0.80▼$1.2152-Week Range$0.50▼$2.73Volume202,050 shsAverage Volume292,727 shsMarket Capitalization$39.02 millionP/E RatioN/ADividend YieldN/APrice Target$4.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Applied Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,184.3% Upside$10.42 Price TargetShort InterestHealthy0.87% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.94Based on 4 Articles This WeekInsider TradingSelling Shares$19,950 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector116th out of 1,004 stocksPharmaceutical Preparations Industry44th out of 489 stocks 3.3 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.42, Applied Therapeutics has a forecasted upside of 1,184.3% from its current price of $0.81.Amount of Analyst CoverageApplied Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.87% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Applied Therapeutics has recently decreased by 17.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Therapeutics is -0.88. Previous Next 2.7 News and Social Media Coverage News SentimentApplied Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Applied Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 22 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,950.00 in company stock.Percentage Held by Insiders17.00% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Therapeutics has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Applied Therapeutics (NASDAQ:APLT) StockApplied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.Read More Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLT Stock News HeadlinesMarch 31, 2023 | americanbankingnews.comApplied Therapeutics, Inc. (NASDAQ:APLT) Sees Significant Decline in Short InterestMarch 23, 2023 | finance.yahoo.comApplied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial ResultsApril 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.March 18, 2023 | finance.yahoo.comQuite a few insiders invested in Applied Therapeutics, Inc. (NASDAQ:APLT) last year which is positive news for shareholdersMarch 1, 2023 | finance.yahoo.comApplied Therapeutics to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 24, 2023 | finance.yahoo.comApplied Therapeutics Reveals Pivotal Study Data In Hereditary NeuropathyFebruary 16, 2023 | msn.comApplied Therapeutics rises ~10% as AT-007 shows efficacy in phase 3 trial for muscle disorderFebruary 16, 2023 | finance.yahoo.comApplied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) DeficiencyApril 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.February 9, 2023 | finance.yahoo.comApplied Therapeutics to Present at the SVB Securities Global Biopharma ConferenceJanuary 21, 2023 | forbes.comApplied TherapeuticsJanuary 4, 2023 | msn.comWhy Applied Therapeutics Shares Are Seeing Blue SkiesJanuary 4, 2023 | uk.finance.yahoo.comApplied Therapeutics, Inc. (APLT)November 9, 2022 | finance.yahoo.comApplied Therapeutics Reports Third Quarter 2022 Financial ResultsOctober 31, 2022 | finance.yahoo.comApplied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022October 25, 2022 | finance.yahoo.comApplied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic CardiomyopathyOctober 9, 2022 | finance.yahoo.comInsiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62October 6, 2022 | marketwatch.comApplied Therapeutics Down 33% on Clinical Trial UpdateOctober 6, 2022 | finance.yahoo.comApplied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical SignificanceOctober 6, 2022 | markets.businessinsider.comApplied Therapeutics: AT-007 Trial Shows Positive Data Trend; Yet To Reach Statistical SignificanceOctober 6, 2022 | finance.yahoo.comApplied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded FormatSeptember 2, 2022 | finance.yahoo.comBears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' NowAugust 16, 2022 | nasdaq.comWe're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn RateAugust 12, 2022 | msn.comRecap: Applied Therapeutics Q2 EarningsAugust 12, 2022 | finance.yahoo.comApplied Therapeutics Reports Second Quarter 2022 Financial ResultsJuly 28, 2022 | finance.yahoo.comApplied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation ConferenceJune 23, 2022 | markets.businessinsider.comNasdaq Jumps Over 100 Points; Applied Therapeutics Shares PlummetSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLT Company Calendar Last Earnings3/23/2023Today4/01/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLT CUSIPN/A CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees34Year Founded2017Price Target and Rating Average Stock Price Forecast$10.42 High Stock Price Forecast$23.00 Low Stock Price Forecast$2.25 Forecasted Upside/Downside+408.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-383.75% Return on Assets-131.25% Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio1.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book10.14Miscellaneous Outstanding Shares48,110,000Free Float39,935,000Market Cap$39.02 million OptionableNot Optionable Beta1.90 Social Links Key ExecutivesShoshana ShendelmanChairman, President, CEO & SecretarySteven OrtegaChief Financial & Accounting OfficerRiccardo PerfettiChief Medical OfficerAdam HansardChief Commercial OfficerKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSELAVA TherapeuticsNASDAQ:LVTXAcurx PharmaceuticalsNASDAQ:ACXPHookipa PharmaNASDAQ:HOOKProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 37,538 shares on 2/15/2023Ownership: 0.129%Alyeska Investment Group L.P.Sold 6,195,161 shares on 2/14/2023Ownership: 2.638%Point72 Asset Management L.P.Sold 1,000,000 shares on 2/14/2023Ownership: 1.498%Pura Vida Investments LLCBought 101,654 shares on 2/14/2023Ownership: 0.212%Renaissance Technologies LLCSold 16,311 shares on 2/13/2023Ownership: 0.662%View All Insider TransactionsView All Institutional Transactions APLT Stock - Frequently Asked Questions Should I buy or sell Applied Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLT shares. View APLT analyst ratings or view top-rated stocks. What is Applied Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued twelve-month target prices for Applied Therapeutics' shares. Their APLT share price forecasts range from $2.25 to $23.00. On average, they predict the company's share price to reach $10.42 in the next year. This suggests a possible upside of 1,184.3% from the stock's current price. View analysts price targets for APLT or view top-rated stocks among Wall Street analysts. How have APLT shares performed in 2023? Applied Therapeutics' stock was trading at $0.76 at the beginning of the year. Since then, APLT shares have increased by 6.7% and is now trading at $0.8111. View the best growth stocks for 2023 here. Are investors shorting Applied Therapeutics? Applied Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 417,000 shares, a drop of 17.3% from the February 28th total of 504,100 shares. Based on an average daily volume of 279,900 shares, the days-to-cover ratio is presently 1.5 days. View Applied Therapeutics' Short Interest. When is Applied Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our APLT earnings forecast. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) released its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.16) earnings per share (EPS) for the quarter. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and Raytheon Technologies (RTX). When did Applied Therapeutics IPO? (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager. What is Applied Therapeutics' stock symbol? Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT." How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Applied Therapeutics' stock price today? One share of APLT stock can currently be purchased for approximately $0.81. How much money does Applied Therapeutics make? Applied Therapeutics (NASDAQ:APLT) has a market capitalization of $39.02 million. The company earns $-82,510,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. How can I contact Applied Therapeutics? Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The official website for the company is www.appliedtherapeutics.com. The company can be reached via phone at (212) 220-9226 or via email at maeve@argotpartners.com. This page (NASDAQ:APLT) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.